{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:51:24Z","timestamp":1788504684199,"version":"build-2803163510"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11102-026-01637-1","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:58:26Z","timestamp":1770350306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of sex on mortality in patients with pituitary adenomas"],"prefix":"10.1007","volume":"29","author":[{"given":"Elena V.","family":"Varlamov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Akirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica L.","family":"Gheorghiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"6","key":"1637_CR1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G et al (2022) Clinical biology of the pituitary adenoma. Endocr Rev 43(6):1003\u201337","journal-title":"Endocr Rev"},{"issue":"3","key":"1637_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","volume":"49","author":"AF Daly","year":"2020","unstructured":"Daly AF, Beckers A (2020) The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am 49(3):347\u2013355","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"1637_CR3","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s40618-024-02356-9","volume":"47","author":"F Bioletto","year":"2024","unstructured":"Bioletto F, Sibilla M, Gasco V, Ghigo E, Grottoli S (2024) Excess mortality in patients with non-functioning pituitary adenoma: a systematic review and meta-analysis. J Endocrinol Invest 47(9):2143\u20132155","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"1637_CR4","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","volume":"13","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Varlamov EV, Akirov A, Langlois F, Petersenn S, Melmed S (2025) Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 13(10):874\u2013890","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1637_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10(11):804\u2013826","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10444","key":"1637_CR6","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1016\/S0140-6736(24)00342-8","volume":"403","author":"M Fleseriu","year":"2024","unstructured":"Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S (2024) Hypopituitarism. Lancet 403(10444):2632\u201348","journal-title":"Lancet"},{"issue":"8","key":"1637_CR7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","volume":"107","author":"P Limumpornpetch","year":"2022","unstructured":"Limumpornpetch P, Morgan AW, Tiganescu A, Baxter PD, Nyawira Nyaga V, Pujades-Rodriguez M et al (2022) The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality. J Clin Endocrinol Metab 107(8):2377\u201388","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1637_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11102-020-01084-6","volume":"24","author":"JS Oh","year":"2021","unstructured":"Oh JS, Kim HJ, Hann HJ, Kang TU, Kim DS, Kang MJ et al (2021) Incidence, mortality, and cardiovascular diseases in pituitary adenoma in korea: a nationwide population-based study. Pituitary 24(1):38\u201347","journal-title":"Pituitary"},{"issue":"1","key":"1637_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","volume":"179","author":"F Bolfi","year":"2018","unstructured":"Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS (2018) Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 179(1):59\u201371","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1637_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/EJE-15-0967","volume":"174","author":"G Ntali","year":"2016","unstructured":"Ntali G, Capatina C, Fazal-Sanderson V, Byrne JV, Cudlip S, Grossman AB et al (2016) Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. Eur J Endocrinol 174(2):137\u201345","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1637_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-21-0216","volume":"185","author":"S Crisafulli","year":"2021","unstructured":"Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G et al (2021) Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol 185(2):251\u2013263","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1637_CR12","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/EJE-19-1023","volume":"182","author":"NF Lenders","year":"2020","unstructured":"Lenders NF, McCormack AI, Ho KKY (2020) Management of endocrine disease: does gender matter in the management of acromegaly? Eur J Endocrinol 182(5):R67\u2013R82","journal-title":"Eur J Endocrinol"},{"key":"1637_CR13","doi-asserted-by":"publisher","first-page":"1348972","DOI":"10.3389\/fendo.2024.1348972","volume":"15","author":"S Galoiu","year":"2024","unstructured":"Galoiu S, Toma ID, Tanasie DI, Barbulescu A, Baciu I, Niculescu DA et al (2024) High mortality risk among women with acromegaly still persists. Front Endocrinol (Lausanne) 15:1348972","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1637_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1530\/EJE-21-0729","volume":"186","author":"S Arnardottir","year":"2022","unstructured":"Arnardottir S, Jaras J, Burman P, Berinder K, Dahlqvist P, Erfurth EM et al (2022) Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. Eur J Endocrinol 186(3):329\u201339","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1637_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12020-022-03275-6","volume":"80","author":"CM Falch","year":"2023","unstructured":"Falch CM, Olarescu NC, Bollerslev J, Dekkers OM, Heck A (2023) Trends in incidence and mortality risk for acromegaly in norway: a cohort study. Endocrine 80(1):152\u2013159","journal-title":"Endocrine"},{"issue":"6","key":"1637_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/EJE-20-0019","volume":"182","author":"D Esposito","year":"2020","unstructured":"Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2020) Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol 182(6):523\u2013531","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1637_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2265.1980.tb03135.x","volume":"12","author":"L Alexander","year":"1980","unstructured":"Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12(1):71\u201379","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1637_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF03344942","volume":"16","author":"J Etxabe","year":"1993","unstructured":"Etxabe J, Gaztambide S, Latorre P, Vazquez JA (1993) Acromegaly: an epidemiological study. J Endocrinol Invest 16(3):181\u2013187","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"1637_CR19","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1210\/jc.2004-1381","volume":"90","author":"R Kauppinen-Makelin","year":"2005","unstructured":"Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H et al (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7):4081\u20136","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1637_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","volume":"26","author":"JD Nabarro","year":"1987","unstructured":"Nabarro JD (1987) Acromegaly. Clin Endocrinol (Oxf) 26(4):481\u2013512","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"1637_CR21","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1210\/jcem.83.10.5111","volume":"83","author":"A Abosch","year":"1998","unstructured":"Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83(10):3411\u20133418","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1637_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667\u2013674","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1637_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00701-004-0466-2","volume":"147","author":"R Trepp","year":"2005","unstructured":"Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER (2005) Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 147(3):243\u2013251 discussion 50\u2009\u2013\u20091","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"1637_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1530\/ERC-16-0106","volume":"23","author":"E Ritvonen","year":"2016","unstructured":"Ritvonen E, Loyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P et al (2016) Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer 23(6):469\u201380","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"1637_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ejendo\/lvad106","volume":"189","author":"J Kim","year":"2023","unstructured":"Kim J, Hong N, Choi J, Moon JH, Kim EH, Hong JW et al (2023) Sex differences in mortality in patients with acromegaly: a nationwide cohort study in Korea. Eur J Endocrinol 189(2):225\u2013234","journal-title":"Eur J Endocrinol"},{"key":"1637_CR26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz317","author":"KH Park","year":"2020","unstructured":"Park KH, Lee EJ, Seo GH, Ku CR (2020) Risk for acromegaly-related comorbidities by sex in Korean acromegaly. J Clin Endocrinol Metab\u00a0105(4):e1815\u2013e1826.\u00a0https:\/\/doi.org\/10.1210\/clinem\/dgz317","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1637_CR27","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1210\/clinem\/dgad141","volume":"108","author":"B Biagetti","year":"2023","unstructured":"Biagetti B, Iglesias P, Villar-Taibo R, Moure MD, Paja M, Araujo-Castro M et al (2023) Mortality in acromegaly diagnosed in older individuals in Spain is higher in women compared to the general Spanish population. J Clin Endocrinol Metab 108(9):2193\u20132202","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1637_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","volume":"157","author":"M Bex","year":"2007","unstructured":"Bex M, Abs R, T\u2019Sjoen G, Mockel J, Velkeniers B, Muermans K et al (2007) AcroBel\u2013the Belgian registry on acromegaly: a survey of the \u2018real-life\u2019 outcome in 418 acromegalic subjects. Eur J Endocrinol 157(4):399\u2013409","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1637_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/EJE-13-0166","volume":"169","author":"F Bogazzi","year":"2013","unstructured":"Bogazzi F, Colao A, Rossi G, Lombardi M, Urbani C, Sardella C et al (2013) Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur J Endocrinol 169(3):367\u2013376","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1637_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-16-0117","volume":"175","author":"J Dal","year":"2016","unstructured":"Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L et al (2016) Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol 175(3):181\u2013190","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1637_CR31","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E et al (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99(12):4438\u20134446","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1637_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/EJE-19-0794","volume":"182","author":"NA Tritos","year":"2020","unstructured":"Tritos NA, Mattsson AF, Vila G, Biller BMK, Klibanski A, Valluri S et al (2020) All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Eur J Endocrinol 182(3):285\u201392","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1637_CR33","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s40618-023-02257-3","volume":"47","author":"M Arosio","year":"2024","unstructured":"Arosio M, Sciannameo V, Contarino A, Berchialla P, Puglisi S, Pesatori AC et al (2024) Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy. J Endocrinol Invest 47(6):1457\u20131465","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1637_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1530\/EJE-18-0015","volume":"178","author":"D Esposito","year":"2018","unstructured":"Esposito D, Ragnarsson O, Granfeldt D, Marlow T, Johannsson G, Olsson DS (2018) Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur J Endocrinol 178(5):459\u2013469","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1637_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1530\/EJE-12-0084","volume":"167","author":"M Arosio","year":"2012","unstructured":"Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189\u201398","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1637_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","volume":"19","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S (2023) An individualized approach to the management of Cushing disease. Nat Rev Endocrinol 19(10):581\u2013599","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1637_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jama.2023.11305","volume":"330","author":"M Reincke","year":"2023","unstructured":"Reincke M, Fleseriu M (2023) Cushing syndrome: a review. JAMA 330(2):170\u2013181","journal-title":"JAMA"},{"issue":"2","key":"1637_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/ejendo\/lvae098","volume":"191","author":"Y Rudman","year":"2024","unstructured":"Rudman Y, Fleseriu M, Dery L, Masri-Iraqi H, Sasson L, Shochat T et al (2024) Endogenous Cushing\u2019s syndrome and cancer risk. Eur J Endocrinol 191(2):223\u201331","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1637_CR39","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1210\/clinem\/dgae405","volume":"110","author":"WC Wu","year":"2025","unstructured":"Wu WC, Wu JL, Huang TS, Li CY, Li HY (2025) Cushing syndrome is associated with a higher risk of Cancer-A nationwide cohort study. J Clin Endocrinol Metab 110(5):1419\u20131426","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1637_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/ejendo\/lvaf028","volume":"192","author":"Y Rudman","year":"2025","unstructured":"Rudman Y, Fleseriu M, Masri-Iraqi H, Shochat T, Kushnir S, Shimon I et al (2025) Impact of remission status in endogenous Cushing\u2019s syndrome on cancer incidence. Eur J Endocrinol 192(3):266\u201376","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1637_CR41","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1530\/EJE-13-0320","volume":"169","author":"M Yaneva","year":"2013","unstructured":"Yaneva M, Kalinov K, Zacharieva S (2013) Mortality in cushing\u2019s syndrome: data from 386 patients from a single tertiary referral center. Eur J Endocrinol 169(5):621\u2013627","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1637_CR42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1210\/jc.2010-1942","volume":"96","author":"RN Clayton","year":"2011","unstructured":"Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in cushing\u2019s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96(3):632\u2013642","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1637_CR43","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2012-3582","volume":"98","author":"OM Dekkers","year":"2013","unstructured":"Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP et al (2013) Multisystem morbidity and mortality in cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab 98(6):2277\u20132284","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1637_CR44","doi-asserted-by":"publisher","first-page":"e2035","DOI":"10.1210\/clinem\/dgab058","volume":"106","author":"MH Schernthaner-Reiter","year":"2021","unstructured":"Schernthaner-Reiter MH, Siess C, Micko A, Zauner C, Wolfsberger S, Scheuba C et al (2021) Acute and Life-threatening complications in Cushing syndrome: Prevalence, Predictors, and mortality. J Clin Endocrinol Metab 106(5):e2035\u2013e46","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1637_CR45","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11102-023-01343-2","volume":"26","author":"A Mondin","year":"2023","unstructured":"Mondin A, Ceccato F, Voltan G, Mazzeo P, Manara R, Denaro L et al (2023) Complications and mortality of Cushing\u2019s disease: report on data collected over a 20-year period at a referral centre. Pituitary 26(5):551\u201360","journal-title":"Pituitary"},{"issue":"5","key":"1637_CR46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1530\/EJE-19-0464","volume":"181","author":"E Valassi","year":"2019","unstructured":"Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R et al (2019) High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: results from the ERCUSYN registry. Eur J Endocrinol 181(5):461\u201372","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1637_CR47","doi-asserted-by":"publisher","first-page":"101521","DOI":"10.1016\/j.beem.2021.101521","volume":"35","author":"OA Hakami","year":"2021","unstructured":"Hakami OA, Ahmed S, Karavitaki N (2021) Epidemiology and mortality of Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35(1):101521","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"1637_CR48","doi-asserted-by":"publisher","first-page":"bvac045","DOI":"10.1210\/jendso\/bvac045","volume":"6","author":"D Bengtsson","year":"2022","unstructured":"Bengtsson D, Ragnarsson O, Berinder K, Dahlqvist P, Eden Engstrom B, Ekman B et al (2022) Increased mortality persists after treatment of Cushing\u2019s disease: a matched nationwide cohort study. J Endocr Soc 6(6):bvac045","journal-title":"J Endocr Soc"},{"key":"1637_CR49","doi-asserted-by":"crossref","unstructured":"Loughrey PB, Herron B, Cooke S, Weir P, Smyth JE, Mullan KR et al (2024) Insights on epidemiology, morbidity and mortality of Cushing\u2019s disease in Northern Ireland. Endocr Relat Cancer 31(9)","DOI":"10.1530\/ERC-24-0028"},{"issue":"8","key":"1637_CR50","doi-asserted-by":"publisher","first-page":"e13113","DOI":"10.1111\/jne.13113","volume":"34","author":"LT Braun","year":"2022","unstructured":"Braun LT, Vogel F, Reincke M (2022) Long-term morbidity and mortality in patients with Cushing\u2019s syndrome. J Neuroendocrinol 34(8):e13113","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"1637_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ejendo\/lvae069","volume":"191","author":"S Germann","year":"2024","unstructured":"Germann S, Wimmer R, Laager R, Mueller B, Schuetz P, Kaegi-Braun N et al (2024) Long-term outcomes in patients with Cushing\u2019s disease vs nonfunctioning pituitary adenoma after pituitary surgery: an active-comparator cohort study. Eur J Endocrinol 191(1):97\u2013105","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1637_CR52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ecl.2018.02.005","volume":"47","author":"P Javanmard","year":"2018","unstructured":"Javanmard P, Duan D, Geer EB (2018) Mortality in patients with endogenous cushing\u2019s syndrome. Endocrinol Metab Clin North Am 47(2):313\u2013333","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"1637_CR53","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1530\/EJE-13-0569","volume":"169","author":"G Ntali","year":"2013","unstructured":"Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M et al (2013) Mortality in cushing\u2019s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 169(5):715\u2013723","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1637_CR54","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1210\/jc.2006-2112","volume":"92","author":"OM Dekkers","year":"2007","unstructured":"Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH et al (2007) Mortality in patients treated for cushing\u2019s disease is increased, compared with patients treated for nonfunctioning pituitary Macroadenoma. J Clin Endocrinol Metab 92(3):976\u2013981","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1637_CR55","doi-asserted-by":"publisher","first-page":"e1362","DOI":"10.1210\/clinem\/dgaa752","volume":"106","author":"CH Ahn","year":"2021","unstructured":"Ahn CH, Kim JH, Park MY, Kim SW (2021) Epidemiology and comorbidity of adrenal Cushing syndrome: a nationwide cohort study. J Clin Endocrinol Metab 106(3):e1362\u2013e72","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1637_CR56","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/EJE-14-0556","volume":"172","author":"FM van Haalen","year":"2015","unstructured":"van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM (2015) Management of endocrine disease: mortality remains increased in Cushing\u2019s disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol 172(4):R143\u20139","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1637_CR57","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","volume":"4","author":"RN Clayton","year":"2016","unstructured":"Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, Ntali G et al (2016) Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. The Lancet Diabetes & Endocrinology 4(7):569\u201376","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"4","key":"1637_CR58","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ejendo\/lvaf059","volume":"192","author":"A Akirov","year":"2025","unstructured":"Akirov A, Fleseriu M, Masri-Iraqi H, Shochat T, Kushnir S, Shimon I et al (2025) Mortality in Cushing\u2019s syndrome: declining over 2 decades but remaining higher than the general population. Eur J Endocrinol 192(4):445\u201355","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1637_CR59","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1210\/clinem\/dgad453","volume":"109","author":"S Puglisi","year":"2024","unstructured":"Puglisi S, Perini AME, Botto C, Oliva F, Terzolo M (2024) Long-term consequences of Cushing syndrome: a systematic literature review. J Clin Endocrinol Metab 109(3):e901\u2013e19","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1637_CR60","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EJE-20-1309","volume":"184","author":"EV Varlamov","year":"2021","unstructured":"Varlamov EV, Langlois F, Vila G, Fleseriu M (2021) Management of endocrine disease: cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing\u2019s syndrome: a practical approach. Eur J Endocrinol 184(5):R207\u2013R24","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1637_CR61","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s11102-022-01261-9","volume":"25","author":"RA Feelders","year":"2022","unstructured":"Feelders RA, Nieman LK (2022) Hypercoagulability in Cushing\u2019s syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols. Pituitary 25(5):746\u2013749","journal-title":"Pituitary"},{"issue":"1","key":"1637_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ejendo\/lvad176","volume":"190","author":"K Isand","year":"2024","unstructured":"Isand K, Feelders R, Brue T, Toth M, Deutschbein T, Reincke M et al (2024) High prevalence of venous thrombotic events in Cushing\u2019s syndrome: data from ERCUSYN and details in relation to surgery. Eur J Endocrinol 190(1):75\u201385","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1637_CR63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","volume":"40","author":"J Etxabe","year":"1994","unstructured":"Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40(4):479\u2013484","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1637_CR64","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1210\/jc.2011-2957","volume":"97","author":"ZK Hassan-Smith","year":"2012","unstructured":"Hassan-Smith ZK, Sherlock M, Reulen RC, Arlt W, Ayuk J, Toogood AA et al (2012) Outcome of Cushing\u2019s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 97(4):1194\u2013201","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1637_CR65","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1210\/jc.2018-02524","volume":"104","author":"O Ragnarsson","year":"2019","unstructured":"Ragnarsson O, Olsson DS, Papakokkinou E, Chantzichristos D, Dahlqvist P, Segerstedt E et al (2019) Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study. J Clin Endocrinol Metab 104(6):2375\u201384","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1637_CR66","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1210\/clinem\/dgaa774","volume":"106","author":"P Roldan-Sarmiento","year":"2021","unstructured":"Roldan-Sarmiento P, Lam-Chung CE, Hinojosa-Amaya JM, Morales-Garcia M, Guillen-Placencia MF, Perez-Flores GE et al (2021) Diabetes, active disease, and afternoon serum cortisol levels predict Cushing\u2019s disease mortality: a cohort study. J Clin Endocrinol Metab 106(1):e103\u2013e11","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1637_CR67","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1210\/jc.2012-2893","volume":"98","author":"JK Lambert","year":"2013","unstructured":"Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB (2013) Predictors of mortality and long-term outcomes in treated cushing\u2019s disease: a study of 346 patients. J Clin Endocrinol Metab 98(3):1022\u20131030","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1637_CR68","doi-asserted-by":"publisher","first-page":"e13114","DOI":"10.1111\/jne.13114","volume":"34","author":"E Valassi","year":"2022","unstructured":"Valassi E (2022) Clinical presentation and etiology of Cushing\u2019s syndrome: data from ERCUSYN. J Neuroendocrinol 34(8):e13114","journal-title":"J Neuroendocrinol"},{"key":"1637_CR69","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3389\/fendo.2019.00580","volume":"10","author":"LHA Broersen","year":"2019","unstructured":"Broersen LHA, van Haalen FM, Kienitz T, Biermasz NR, Strasburger CJ, Dekkers OM et al (2019) Sex differences in presentation but not in outcome for ACTH-dependent Cushing\u2019s syndrome. Front Endocrinol (Lausanne) 10:580","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1637_CR70","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cen.12299","volume":"80","author":"M Zilio","year":"2014","unstructured":"Zilio M, Barbot M, Ceccato F, Camozzi V, Bilora F, Casonato A et al (2014) Diagnosis and complications of cushing\u2019s disease: gender-related differences. Clin Endocrinol (Oxf) 80(3):403\u2013410","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1637_CR71","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1210\/jc.2002-021518","volume":"88","author":"F Pecori Giraldi","year":"2003","unstructured":"Pecori Giraldi F, Moro M, Cavagnini F, Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of E (2003) Gender-related differences in the presentation and course of cushing\u2019s disease. J Clin Endocrinol Metab 88(4):1554\u20131558","journal-title":"J Clin Endocrinol Metab"},{"issue":"10244","key":"1637_CR72","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0140-6736(20)30543-2","volume":"396","author":"M Walli-Attaei","year":"2020","unstructured":"Walli-Attaei M, Joseph P, Rosengren A, Chow CK, Rangarajan S, Lear SA et al (2020) Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 396(10244):97\u2013109","journal-title":"Lancet"},{"issue":"1","key":"1637_CR73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/cen.13498","volume":"88","author":"KA Toulis","year":"2018","unstructured":"Toulis KA, Robbins T, Reddy N, Balachandran K, Gokhale K, Wijesinghe H et al (2018) Males with prolactinoma are at increased risk of incident cardiovascular disease. Clin Endocrinol (Oxf) 88(1):71\u201376","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"1637_CR74","first-page":"e42911","volume":"15","author":"MS Baba","year":"2023","unstructured":"Baba MS, Islam Mir SU, Bhat MH, Laway BA, Misgar RA (2023) Gender disparities in prolactinomas: unravelling clinical patterns, metabolic variations, and treatment responses. Cureus 15(8):e42911","journal-title":"Cureus"},{"issue":"3","key":"1637_CR75","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3803\/EnM.2021.1000","volume":"36","author":"JS Park","year":"2021","unstructured":"Park JS, Yun SJ, Lee JK, Park SY, Chin SO (2021) Descriptive epidemiology and survival analysis of prolactinomas and cushing\u2019s disease in Korea. Endocrinol Metab (Seoul) 36(3):688\u2013696","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"8","key":"1637_CR76","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1530\/EC-17-0171","volume":"6","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre E, Newey PJ, Bevan JS, Leese GP (2017) Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr Connect 6(8):580\u2013588","journal-title":"Endocr Connect"},{"issue":"8","key":"1637_CR77","doi-asserted-by":"publisher","first-page":"e1652","DOI":"10.1210\/clinem\/dgae087","volume":"109","author":"AS Papazoglou","year":"2024","unstructured":"Papazoglou AS, Leite AR, Moysidis DV, Anastasiou V, Daios S, Borges-Canha M et al (2024) Serum prolactin levels and mortality in adults without prolactinoma: A Meta-Analysis. J Clin Endocrinol Metab 109(8):e1652\u2013e64","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1637_CR78","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0043-107243","volume":"49","author":"J Krogh","year":"2017","unstructured":"Krogh J, Selmer C, Torp-Pedersen C, Gislason GH, Kistorp C (2017) Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm Metab Res 49(6):411\u2013417","journal-title":"Horm Metab Res"},{"issue":"6","key":"1637_CR79","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11102-025-01594-1","volume":"28","author":"I Ayalon-Dangur","year":"2025","unstructured":"Ayalon-Dangur I, Shimon I, Shochat T, Kushnir S, Rudman Y, Dotan I et al (2025) Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study. Pituitary 28(6):116","journal-title":"Pituitary"},{"issue":"10","key":"1637_CR80","doi-asserted-by":"publisher","first-page":"R375","DOI":"10.1530\/ERC-20-0136","volume":"27","author":"MP Yavropoulou","year":"2020","unstructured":"Yavropoulou MP, Tsoli M, Barkas K, Kaltsas G, Grossman A (2020) The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs). Endocr Relat Cancer 27(10):R375\u2013R90","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"1637_CR81","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41574-025-01134-8","volume":"21","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Gurnell M, McCormack A, Fukuoka H, Glezer A, Langlois F et al (2025) Pituitary incidentaloma: a pituitary society international consensus guideline statement. Nat Rev Endocrinol 21(10):638\u2013655","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"1637_CR82","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1210\/jc.2015-1475","volume":"100","author":"DS Olsson","year":"2015","unstructured":"Olsson DS, Nilsson AG, Bryngelsson IL, Trimpou P, Johannsson G, Andersson E (2015) Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Swedish nationwide study. J Clin Endocrinol Metab 100(7):2651\u20132658","journal-title":"J Clin Endocrinol Metab"},{"key":"1637_CR83","doi-asserted-by":"publisher","first-page":"1653376","DOI":"10.3389\/fendo.2025.1653376","volume":"16","author":"G Vargas-Ortega","year":"2025","unstructured":"Vargas-Ortega G, Ramirez-Garcia EM, Balcazar-Hernandez L, Rendon-Macias ME, Romero-Gameros CA, Gonzalez-Virla B et al (2025) Increased mortality in patients with non-functioning pituitary tumors: a study in a tertiary center. Front Endocrinol (Lausanne) 16:1653376","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1637_CR84","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4183\/aeb.2013.219","volume":"9","author":"SIS Galoiu","year":"2013","unstructured":"Galoiu SIS, Baciu I, Coculescu M (2013) Reduced life expectancy in women with nonfunctioning pituitary adenomas and concomitant hypopituitarism. Acta Endo (Buc) 9(2):219\u2013228","journal-title":"Acta Endo (Buc)"},{"key":"1637_CR85","doi-asserted-by":"crossref","unstructured":"Galoiu SSS, Baciu I, Trifanescu RA, Niculescu D, Capatina C, Radian S, Dumitrascu A, Caragheorgheopol A, Poiana C (2018) Time trends of mortality in patients with GH secreting and non-functioning pituitary adenoma. Endocr Abstracts 56:OC13.2","DOI":"10.1530\/endoabs.56.OC13.2"},{"issue":"1","key":"1637_CR86","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11102-007-0018-x","volume":"10","author":"EH Nielsen","year":"2007","unstructured":"Nielsen EH, Lindholm J, Laurberg P, Bjerre P, Christiansen JS, Hagen C et al (2007) Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary 10(1):67\u201373","journal-title":"Pituitary"},{"issue":"5","key":"1637_CR87","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/cen.13141","volume":"85","author":"MW O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly MW, Reulen RC, Gupta S, Thompson CA, Dineen R, Goulden EL et al (2016) <article-title update=\"added\">ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long\u2010term follow\u2010up of 519 patients in two large European centres. Clin Endocrinol (Oxf) 85(5):748\u201356","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9254","key":"1637_CR88","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","volume":"357","author":"JW Tomlinson","year":"2001","unstructured":"Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS et al (2001) Association between premature mortality and hypopituitarism. West Midlands prospective hypopituitary study group. Lancet 357(9254):425\u2013431","journal-title":"Lancet"},{"issue":"10","key":"1637_CR89","doi-asserted-by":"publisher","first-page":"E1938","DOI":"10.1210\/jc.2012-2432","volume":"97","author":"T Zueger","year":"2012","unstructured":"Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E et al (2012) Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab 97(10):E1938\u2013E1942","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1637_CR90","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11102-016-0764-8","volume":"20","author":"DS Olsson","year":"2017","unstructured":"Olsson DS, Bryngelsson IL, Ragnarsson O (2017) Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study. Pituitary 20(2):218\u2013224","journal-title":"Pituitary"},{"issue":"4","key":"1637_CR91","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3171\/JNS\/2008\/108\/4\/0736","volume":"108","author":"EF Chang","year":"2008","unstructured":"Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB et al (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108(4):736\u201345","journal-title":"J Neurosurg"},{"key":"1637_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040518","author":"PK Hsiao","year":"2019","unstructured":"Hsiao PK, Chang CL, Yuan KS, Wu ATH, Wu SY (2019) Results of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, and transsphenoidal surgery in nonfunctioning pituitary macroadenoma. J Clin Med\u00a08(4):518.\u00a0https:\/\/doi.org\/10.3390\/jcm8040518","journal-title":"J Clin Med"},{"issue":"3","key":"1637_CR93","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1210\/jc.2014-3697","volume":"100","author":"NC van Varsseveld","year":"2015","unstructured":"van Varsseveld NC, van Bunderen CC, Ubachs DH, Franken AA, Koppeschaar HP, van der Lely AJ et al (2015) Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the Dutch National registry of growth hormone treatment in adults. J Clin Endocrinol Metab 100(3):1104\u20131112","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1637_CR94","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4183\/aeb.2017.476","volume":"13","author":"ML Gheorghiu","year":"2017","unstructured":"Gheorghiu ML, Fleseriu M (2017) Stereotactic radiation therapy in pituitary adenomas, is it better than conventional radiation therapy? Acta Endocrinol (Buchar) 13(4):476\u2013490","journal-title":"Acta Endocrinol (Buchar)"},{"issue":"1","key":"1637_CR95","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-16-0173","volume":"175","author":"DS Olsson","year":"2016","unstructured":"Olsson DS, Bryngelsson IL, Ragnarsson O (2016) Higher incidence of morbidity in women than men with non-functioning pituitary adenoma: a Swedish nationwide study. Eur J Endocrinol 175(1):55\u201361","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1637_CR96","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12020-023-03434-3","volume":"82","author":"Z Hussein","year":"2023","unstructured":"Hussein Z, Marcus HJ, Grieve J, Dorward N, Kosmin M, Fersht N et al (2023) Pituitary function at presentation and following therapy in patients with non-functional pituitary macroadenomas: a single centre retrospective cohort study. Endocrine 82(1):143\u2013151","journal-title":"Endocrine"},{"issue":"5","key":"1637_CR97","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40618-020-01379-2","volume":"44","author":"C Di Somma","year":"2021","unstructured":"Di Somma C, Scarano E, de Alteriis G, Barrea L, Riccio E, Arianna R et al (2021) Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. J Endocrinol Invest 44(5):957\u201368","journal-title":"J Endocrinol Invest"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01637-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01637-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:02:25Z","timestamp":1773687745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01637-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01637-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"EVV has received research grants to University from Recordati and Novo Nordisk. AA has received occasional scientific fee for scientific consulting and advisory boards from Medison, CTS pharma, and Neopharm, MF has received scientific consulting fees from Alexion, DebioPharm, Camurus, Crinetics, Recordati, Sparrow and Xeris and research support to University from Alexion, DebioPharm, Crinetics and Sparrow. MLG has no conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"36"}}